NCT04003649View on ClinicalTrials.gov

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

May 26, 2026

Study Completion Date

May 26, 2026

Conditions
Recurrent GlioblastomaRefractory Glioblastoma
Interventions
BIOLOGICAL

IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells

Given ITV/ITC

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Gateway for Cancer Research

OTHER

lead

City of Hope Medical Center

OTHER